Endocrine Abstracts

Objectives: Eversense XL is a fully implantable sensor for continuous glucose monitoring (CGM) that lasts for up to 180 days. Our objective was to perform a survey on user acceptance and satisfaction among our type 1 diabetic patients who had been using the Eversense XL CGM for at least 3 months.

Methods: A questionnaire was devised in which the patients were asked about their experience with the Eversense XL CGM, including:

-Comparison with blood glucose strips and previously used glucose sensors if available

-Perceived accuracy, comfort and ease of use.

-Perceived changes in quality of life, and ability to perform their daily activities including sports

-Overall satisfaction with the device

Visual analogue scales were used for quantitative data. The questionnaires were collected anonymously and with informed consent from the patients. All our type 1 diabetic patients who had been using the Eversense XL monitor for at least 3 months gave their consent and fulfilled the questionnaire

Results: Thirteen patients were included in the survey, mean age 34 ± 5 years, 61.5% male. Five of them (38.5%) had previously used a glucose monitor (Abbott FreeStyle Libre in all cases). All patients were more satisfied with the Eversense XL than with blood glucose strips (by 49.3 ± 11.4%) and their previous glucose monitor (by 13.4 ± 2.5%) 9 patients (69.2%) perceived the Eversense XL as more accurate than blood glucose strips (change 13.6 ± 5.8%) and 3 patients (60%) as more accurate than the previous sensor (change 7.3 ±4.7%). The Eversense XL increased the perceived overall quality of life of 11 patients (84.6%, change 23.2 ± 7.3%), and the perceived ability to perform their daily activities in all patients (change 32.7 ± 9.6%); all the 9 patients who regularly performed sports activities improved their ability to do so (by 63.7 ± 15.6%). The overall satisfaction with the device was rated 79.6 ± 12.8%. Comfort was rated 73.3 ± 15.5%, and ease of use 45.8 ± 29.7%.

Conclsions: The user acceptance and satisfaction with the Eversense XL CGM was high among our type 1 diabetic patients. The general impression was an improvement in their quality of life, and in their perceived ability to perform their daily activities. In particular, their ability to perform sport activities was markedly enhanced.